Jianmin Yang
Canadian Food Inspection Agency(CA)Second Military Medical University(CN)Ludong University(CN)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Canadian Science Centre for Human and Animal Health(CA)Mianyang Central Hospital(CN)Changhai Hospital(CN)Guang’anmen Hospital(CN)Beijing Tsinghua Chang Gung Hospital(CN)Shanghai Maritime University(CN)Tsinghua University(CN)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Myeloid Leukemia Treatments, Hematopoietic Stem Cell Transplantation
Most-Cited Works
- → Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China(2017)247 cited
- → Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial(2019)234 cited
- → Fluidic Multivalent Membrane Nanointerface Enables Synergetic Enrichment of Circulating Tumor Cells with High Efficiency and Viability(2020)165 cited
- → Point Mutation of the Proteasome β5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line(2008)106 cited
- → Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line(2008)89 cited
- → Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line